U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids.

The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.

All things considered, it’s at least as likely to make health outcomes worse as it is to make most people healthier.

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical ...

Alterity Therapeutics (ATHE) announced topline results from the ATH434-201 randomized, double-blind, placebo-controlled Phase 2 clinical trial ...

Robert F. Kennedy Jr., President Donald Trump's choice to be Secretary of Health and Human Services, appears before the ...

LAST weekend, a Filipina recounted her experience in a video after a beauty procedure where she underwent an intravenous (IV) glutathione procedure. That video has already gone viral and shows the ...

"Seeing is believing," the founder of lab company Truvian told me. So I tried its tabletop blood testing device—which ...

For the first time in 30 years, the Food and Drug Administration is updating its claim on what food products can use the word ...

A front-of-package food label would be a great educational tool. The Trump administration should keep it.

The US Food and Drug Administration announced this month that it's effectively banning Red No. 3, the controversial ...

(Nasdaq: IINN, IINNW) ("Inspira," or the "Company"), a leader in innovative medical technology, has announced the addition of new support features to the INSPIRA™ ART100, a system cleared by the U.S.